Search
Naloxone
go.drugbank.com/drugs/DB01183ApprovedInvestigationalVet approvedThere are over-the-counter nasal sprays available. When injected intramuscularly (IM), naloxone acts within three to five minutes. … [L33714,L33719] Naloxone was granted FDA approval on 13 April 1971.[L33709]
Mixtures: OXYCODON COMP EVER 10/5MG, OXYCODON COMP EVER 10/5MGProducts: NALOKSON HIDROKLORUR ENJ.10AMP(D)(ELisocabtagene maraleucel
go.drugbank.com/drugs/DB16582ApprovedInvestigational[A228493] Lisocabtagene maraleucel was granted FDA approval on 5 February 2021 [L31583] and EC approval on 5 April 2022.[L42210] It was later granted Health Canada approval on 6 May 2022. … [L31588] CAR T-cell therapy has changed the treatment of B-cell lymphomas, significantly increasing survival rates over standard therapy.
Nylidrin
go.drugbank.com/drugs/DB06152ApprovedWithdrawnThis effect may help to improve memory/judgment, improve walking ability, and support the healing of frostbite/ulcers [L2283]. … Therefore, the FDA has withdrawn nylidrin from the U.S. market [L2286].
Insulin glargine
go.drugbank.com/drugs/DB00047ApprovedInvestigationalInsulin glargine is also available as the biosimilar, or "follow-on" product, Basaglar in the US and as Abasaglar in the EU. … In 2021, another biosimilar, Semglee (insulin glargine-yfgn),[L34959] became the first interchangeable (with Lantus) biosimilar insulin to receive FDA approval.
Mixtures: SOLİQUA SOLOSTAR 100 U/ML + 33 MCG/ML SC ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 5 KALEM, SOLİQUA SOLOSTAR 100 U/ML + 50 MCG/ML SC ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 5 KALEMProducts: LANTUS® 100 IU/ML, LANTUS ® 100 U / MLTrandolapril
go.drugbank.com/drugs/DB00519ApprovedInvestigationalventricular dysfunction, as an adjunct treatment for congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt
Mixtures: Trandolapril and Verapamil Hydrochloride ER, Trandolapril and Verapamil Hydrochloride ERCilgavimab
go.drugbank.com/drugs/DB16393ApprovedInvestigationalCilgavimab, in combination with [tixagevimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for … [A243351, A243361, L39411] Cilgavimab is not approved for any indication by the FDA.
Tixagevimab
go.drugbank.com/drugs/DB16394ApprovedInvestigationalTixagevimab, in combination with [cilgavimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for … [A243351, A243361, L39411] Tixagevimab is not approved for any indication by the FDA.
Aprocitentan
go.drugbank.com/drugs/DB15059ApprovedInvestigational[A263386,L50261] Aprocitentan was approved by the FDA in March 2024 for the treatment of hypertension in patients inadequately controlled with standard therapy.
Technetium Tc-99m red blood cells
go.drugbank.com/drugs/DB09493ApprovedWithdrawnRadiolabeled red blood cells are re-injected intravenously into the patient for gamma scintigraphic imaging [FDA Label].
Nalbuphine
go.drugbank.com/drugs/DB00844ApprovedInvestigationalIt appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors.